Literature DB >> 16102499

Of circles and spirals: bridging the gap between the leading circle and spiral wave concepts of cardiac reentry.

P Comtois1, J Kneller, S Nattel.   

Abstract

The "leading circle model" was the first detailed attempt at understanding the mechanisms of functional reentry, and remains a widely-used notion in cardiac electrophysiology. The "spiral wave" concept was developed more recently as a result of modern theoretical analysis and is the basis for consideration of reentry mechanisms in present biophysical theory. The goal of this paper is to present these models in a way that is comprehensible to both the biophysical and electrophysiology communities, with the idea of helping clinical and experimental electrophysiologists to understand better the spiral wave concept and of helping biophysicists to understand why the leading circle concept is so attractive and widely used by electrophysiologists. To this end, the main properties of the leading circle and spiral wave models of reentry are presented. Their basic assumptions and determinants are discussed and the predictions of the two concepts with respect to pharmacological responses of arrhythmias are reviewed. A major difference between them lies in the predicted responses to Na(+)-channel blockade, for which the spiral wave paradigm appears more closely to correspond to the results of clinical and experimental observations. The basis of this difference is explored in the context of the fundamental properties of the models.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16102499     DOI: 10.1016/j.eupc.2005.05.011

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  46 in total

Review 1.  Report on the Ion Channel Symposium : Organized by the German Cardiac Society Working Group on Cellular Electrophysiology (AG 18).

Authors:  Niels Voigt; Fleur Mason; Dierk Thomas
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2018-01-08

Review 2.  Genotype influence in responses to therapy for atrial fibrillation.

Authors:  Henry Huang; Dawood Darbar
Journal:  Expert Rev Cardiovasc Ther       Date:  2016-07-15

3.  A mathematical model of the unidirectional block caused by the pulmonary veins for anatomically induced atrial reentry.

Authors:  Sehun Chun
Journal:  J Biol Phys       Date:  2014-05-02       Impact factor: 1.365

4.  Differences in Left Versus Right Ventricular Electrophysiological Properties in Cardiac Dysfunction and Arrhythmogenesis.

Authors:  Cristina E Molina; Jordi Heijman; Dobromir Dobrev
Journal:  Arrhythm Electrophysiol Rev       Date:  2016-05

5.  The anti-influenza drug oseltamivir reduces atrial fibrillation in an experimental whole-heart model.

Authors:  Gerrit Frommeyer; André Mittelstedt; Julian Wolfes; Christian Ellermann; Simon Kochhäuser; Patrick Leitz; Dirk G Dechering; Lars Eckardt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-08-06       Impact factor: 3.000

Review 6.  Investigational antiarrhythmic agents: promising drugs in early clinical development.

Authors:  Jordi Heijman; Shokoufeh Ghezelbash; Dobromir Dobrev
Journal:  Expert Opin Investig Drugs       Date:  2017-07-20       Impact factor: 6.206

Review 7.  Pathophysiology of ventricular tachyarrhythmias : From automaticity to reentry.

Authors:  Andres Enriquez; David S Frankel; Adrian Baranchuk
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2017-05-31

Review 8.  Novel approaches for pharmacological management of atrial fibrillation.

Authors:  Joachim R Ehrlich; Stanley Nattel
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 9.  Atrial Ca2+ signaling in atrial fibrillation as an antiarrhythmic drug target.

Authors:  Dobromir Dobrev
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-09-26       Impact factor: 3.000

10.  Basic concepts of optical mapping techniques in cardiac electrophysiology.

Authors:  Mina Attin; William T Clusin
Journal:  Biol Res Nurs       Date:  2009-07-17       Impact factor: 2.522

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.